Compare ANPA & XTNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANPA | XTNT |
|---|---|---|
| Founded | 2016 | N/A |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.0M | 39.6M |
| IPO Year | 2024 | 2009 |
| Metric | ANPA | XTNT |
|---|---|---|
| Price | $1.16 | $0.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.03 |
| AVG Volume (30 Days) | 18.1K | ★ 147.0K |
| Earning Date | 09-30-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 125.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $53,337,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.14 | $0.27 |
| 52 Week High | $180.64 | $0.84 |
| Indicator | ANPA | XTNT |
|---|---|---|
| Relative Strength Index (RSI) | 26.46 | 35.92 |
| Support Level | N/A | N/A |
| Resistance Level | $2.18 | $0.33 |
| Average True Range (ATR) | 0.10 | 0.03 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 11.34 | 9.29 |
Rich Sparkle Holdings Ltd is a holding company conducting its operations as a professional specialist in the provision of financial printing services such as printing, typesetting and translation, advisory services including Environmental, Social and Governance (ESG) and internal control reporting services and other services including standalone annual general meeting and extraordinary general meeting supporting service and other standalone services, through its sole operating subsidiary in Hong Kong. Its segments include Financial printing services such as printing, typesetting and translation, Advisory services including Environmental, Social and Governance Report and Other services.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.